Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia

Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02992938

Enrollment

Registered

2016-12-14

Start date

2016-12-31

Completion date

2018-09-28

Last updated

2018-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperalgesia, Opioid-Related Disorders

Keywords

Opioid hyperalgesia, Acetazolamide, Remifentanil

Brief summary

Remifentanil is a potent opioid widely used during the administration of general anesthesia. There is a lot of evidence that suggest that the used of remifentanil is associated with the development of hyperalgesia (a reduction of nociceptive thresholds). However, the mechanism of this hyperalgesia is not fully understood. Recently, it was demonstrated that the disruption of the Cl- homeostasis could be involved. Interestingly, this was prevented in a murine model with the administration of Acetazolamide, a carbonic anhydrase inhibitor. In our clinical trial we will try to determine if the preoperative administration of acetazolamide could prevent the hyperalgesia induced by remifentanil in patients scheduled for thyroidectomy with general anesthesia.

Interventions

DRUGAcetazolamide

DRUGPlacebo Oral Tablet

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients scheduled for thyroidectomy with general anesthesia in the University of Chile Clinical Hospital

Exclusion criteria

* Patients ASA III y IV * Chronic pain history * Drug and alcohol abuse * Chronic use of opioid and sedatives * Neuropsychiatric illness * NSAID and other analgesics used the 48 hours previous to the surgery * CMI \> 30

Design outcomes

Primary

Measure	Time frame	Description
Change in the mechanical pain threshold in an area distant to the site of the injury	12-18 hours after the end of the surgery	The threshold will be determine using von Frey monofilaments before the surgery and will be compared 12-18 hours after the end of the surgery

Secondary

Measure	Time frame	Description
Change in the mechanical pain threshold in an area distant to the site of the injury	2 hours after the end of the surgery	—
Postoperative pain	The first postoperative day	A visual analogue scale (VAS; 0, no pain; 100, worst poss- ible pain) will be used to assess pain
Morphine consumption	The first postoperative day	Morphine consumption with a patient controlled analgesia (PCA) in mg

Countries

Chile

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026